RANI Long Call Strategy
RANI (Rani Therapeutics Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI (Rani Therapeutics Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $68.6M, a beta of 0.76 versus the broader market, a 52-week range of 0.387-3.87, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 105 full-time employees. These structural characteristics shape how RANI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.76 places RANI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on RANI?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current RANI snapshot
As of May 15, 2026, spot at $1.10, ATM IV 203.00%, IV rank 42.74%, expected move 58.20%. The long call on RANI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on RANI specifically: RANI IV at 203.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 58.20% (roughly $0.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RANI expiries trade a higher absolute premium for lower per-day decay. Position sizing on RANI should anchor to the underlying notional of $1.10 per share and to the trader's directional view on RANI stock.
RANI long call setup
The RANI long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RANI near $1.10, the first option leg uses a $1.10 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RANI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RANI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.10 | N/A |
RANI long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
RANI long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on RANI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on RANI
Long calls on RANI express a bullish thesis with defined risk; traders use them ahead of RANI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
RANI thesis for this long call
The market-implied 1-standard-deviation range for RANI extends from approximately $0.46 on the downside to $1.74 on the upside. A RANI long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current RANI IV rank near 42.74% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on RANI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RANI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RANI-specific events.
RANI long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RANI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RANI alongside the broader basket even when RANI-specific fundamentals are unchanged. Long-premium structures like a long call on RANI are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RANI chain quotes before placing a trade.
Frequently asked questions
- What is a long call on RANI?
- A long call on RANI is the long call strategy applied to RANI (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RANI stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed RANI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RANI long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RANI long call priced from the end-of-day chain at a 30-day expiry (ATM IV 203.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RANI long call?
- The breakeven for the RANI long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RANI market-implied 1-standard-deviation expected move is approximately 58.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on RANI?
- Long calls on RANI express a bullish thesis with defined risk; traders use them ahead of RANI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current RANI implied volatility affect this long call?
- RANI ATM IV is at 203.00% with IV rank near 42.74%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.